Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA Vaccine Immunogenicity and Safety in Older Adults in China vs Overseas
NCT06551181Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 7
01
Overview
Phase 3, randomised trial of GSK3003899A in respiratory syncytial virus infection (RSV) (3 arms), sponsored by GSK. Primary endpoints: RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 month, Percentage of Participants With Seroresponse for RSV-A Neutralizing Titers at 1 month and 2 more. Started Aug 2024; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06551181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551181.